Lactase

Summary

Lactase (CHEMBL2108505) is a phase-3 clinical-stage enzyme; indicated across 1 condition including lactose intolerance.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 1 condition
• Clinical trials: 9

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108505
Name	Lactase
Type	Enzyme
Max phase	3

Also known as: Beta-galactosidase (aspergillus), G9S0VV191I, Lactase, LACTASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
lactose intolerance	3	MONDO:0100345	EFO:1000062

Clinical trials

Total trials: 9.

Phase distribution

Phase	Trials
Not specified	7
PHASE3	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01145339	PHASE3	COMPLETED	A Non-inferiority, Multicenter and Randomized, Single-Dose Study About a Treatment to Hypolactasia (LAILAI)
NCT01145586	PHASE3	COMPLETED	A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia
NCT05100719	Not specified	NOT_YET_RECRUITING	The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
NCT07088302	Not specified	RECRUITING	Effect OF Lactase Enzyme Supplements ON Intolerance IN Preterm Neonates
NCT07150884	Not specified	RECRUITING	Lactase-Assisted Control Trial On Weight GAin in INfants.
NCT01593631	Not specified	COMPLETED	Acid Lactase in Combination With Yoghurt Bacteria for Improvement of Lactose Digestion in Lactose Malabsorbers
NCT03814668	Not specified	COMPLETED	Effect of Probiotic Supplementation on Lactose Maldigestion Induced by Lactose Solution
NCT05367453	Not specified	COMPLETED	Effect of a Probiotic With High Beta-galactosidase Activity on Patients With Lactose Intolerance
NCT06827405	Not specified	COMPLETED	Comparison of the Effectiveness of Oral Lactase Enzyme and Lactose Free Formula

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).